Polarean Imaging plc (AIM: POLX), the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, notes the publication of a study using Polarean's hyperpolarised gas MRI technology in a study of patients with severe asthma in the April edition of the American Journal of Respiratory and Critical Care Medicine (AJRCCM).
The study, entitled "Sputum Eosinophilia and Magnetic Resonance Imaging Ventilation Heterogeneity in Severe Asthma" is authored by Svenningsen, Eddy, Lim, Cox, Nair and Parraga and can be obtained from the AJRCCM website.
The study looked at patients with severe asthma and investigated the contributions of both inﬂammatory and non-inﬂammatory components of airway disease. A key finding was that MRI scans using hyperpolarized gas were able to identify, for the first time, the airway inﬂammatory (eosinophilia) and non-inﬂammatory contributions (smooth muscle dysfunction) to ventilation heterogeneity in patients with severe asthma.
October 3, 2018
LONDON (Alliance News) - Medical technology company Polarean Imaging PLC on Wednesday said the latest model of its Xenon polariser has been delivered to the radiology department at University of Missouri Health Care.
The polariser will be used in the radiology department's pulmonary imaging research programme.
"We are excited to deliver the newest version of our polariser to University of Missouri Health Care. We are grateful to Dr. Altes, University of Missouri Health Care, and all the skilled researchers there, for the opportunity to work together and continue our research into the clinical applications of this emerging and much needed technology," said Chief Executive Richard Hullihen.